Sanjivani Paranteral Receives 'Buy' Rating from MarketsMOJO, Demonstrates Strong Growth and Profitability

Sanjivani Paranteral, a microcap pharmaceutical company, has recently received a 'Buy' rating from MarketsMOJO on September 6th, 2024. This upgrade comes as no surprise, as the company has consistently shown positive results in the last four quarters.
In terms of financial performance, Sanjivani Paranteral has achieved its highest net sales of Rs 16.44 crore and PBDIT of Rs 2.34 crore in the last quarter. Additionally, its PBT LESS OI has also reached its highest at Rs 2.18 crore. These impressive numbers demonstrate the company's strong growth and profitability.

Moreover, the stock is currently in a bullish range and has shown a significant improvement in its technical trend since June 20th, 2024. It has generated a remarkable 86.32% returns since then. This is further supported by multiple bullish factors such as MACD, Bollinger Band, KST, DOW, and OBV.

It is worth noting that the majority of the company's shareholders are non-institutional, indicating a strong belief in the company's potential. Furthermore, Sanjivani Paranteral has consistently outperformed BSE 500 in the last three annual periods, showcasing its consistent returns over the years.

With all these positive factors in place, it is no surprise that MarketsMOJO has upgraded its rating on Sanjivani Paranteral to 'Buy'. As a microcap company in the pharmaceutical industry, Sanjivani Paranteral has shown great potential and is definitely one to watch out for in the future.